Please be aware that this website is not intended for consumers, as the information provided herein does not refer to finished commercial products that are generally available to the public.
The claims made refer to ingredients only and may not comply with Regulation (EC) No. 1924/2006, the Swiss Federal Act on Foodstuffs and Utility Articles (and related Ordinance), the Swiss Ordinance of the Internal Affairs Department on Information concerning Foodstuffs and Cosmetics, or other relevant regulations in your country. Any claims or statements about the products relating to their health benefits have not been evaluated by the Food and Drug Administration (FDA) and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Any of the ingredients are intended to diagnose, treat, cure, or prevent any disease or health condition.
This website is accessible from various countries around the world. Therefore, it may include statements or information that are not applicable to your country or region.
Linnea SA has been a pioneer in the Cannabinoid active pharmaceutical ingredient (API) industry since it began producing CBD extracts in 2016. …
In October 2024, Linnea team was thrilled to exhibit at CPHI Milan, the premier global gathering for the pharmaceutical industry It has…
The European Directorate for the Quality of Medicines & Healthcare (EDQM) has issued a CEP certificate for our Vincamine product, making Linnea…
Linnea is proud to comply with the new CBD monograph issued by the European Pharmacopoeia. This monograph is applicable for medical prescriptions,…